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Abstract
Background—Risk variants identified so far for colorectal cancer explain only a small 
proportion of familial risk of this cancer, particularly in Asians.
Methods—We performed a genome-wide association study (GWAS) of colorectal cancer in East 
Asians, including 23,572 colorectal cancer cases and 48,700 controls. To identify novel risk loci, 
we selected 60 promising risk variants for replication using data from 58,131 colorectal cancer 
cases and 67,347 controls of European descent. To identify additional risk variants in known 
colorectal cancer loci, we performed conditional analyses in East Asians.
Results—An indel variant, rs67052019 at 1p13.3, was found to be associated with colorectal 
cancer risk at P = 3.9 × 10−8 in Asians (OR per allele deletion = 1.13, 95% confidence interval = 
1.08–1.18). This association was replicated in European descendants using a variant (rs2938616) 
in complete linkage disequilibrium with rs67052019 (P = 7.7 × 10−3). Of the remaining 59 
variants, 12 showed an association at P < 0.05 in the European-ancestry study, including 
rs11108175 and rs9634162 at P < 5 × 10−8 and two variants with an association near the genome-
wide significance level (rs60911071, P = 5.8 × 10−8; rs62558833, P = 7.5 × 10−8)in the combined 
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analyses of Asian- and European-ancestry data. In addition, using data from East Asians, we 
identified 13 new risk variants at 11 loci reported from previous GWAS.
Conclusions—In this large GWAS, we identified three novel risk loci and two highly suggestive 
loci for colorectal cancer risk and provided evidence for potential roles of multiple genes and 
pathways in the etiology of colorectal cancer. In addition, we showed that additional risk variants 
exist in many colorectal cancer risk loci identified previously.
Impact—Our study provides novel data to improve the understanding of the genetic basis for 
colorectal cancer risk.
Introduction
Colorectal cancer is the third most commonly diagnosed cancer in men and the second in 
women, with 1.65 million new cases and almost 835,000 deaths in 2015 (1). Inherited 
genetic susceptibility contributes significantly to the etiology of colorectal cancer (2). Rare 
high-penetrance germline mutations in colorectal cancer predisposition genes (APC, 
MUTYH, MLH1, MSH2, MSH6, PMS2, PTEN, STK11, GREM1, BMPR1A, SMAD4, 
POLE, POLD1, NTHL1, and TP53; refs. 3–5) are estimate to account for less than 10% of 
colorectal cancer cases in the general population (3). Over the past decade, genome-wide 
association studies (GWAS) have identified about 100 independent loci associated with 
colorectal cancer risk (3, 6–13). These common genetic risk variants, however, explain only 
a small proportion of the familial relative risk of colorectal cancers (10, 11, 13), indicating 
that additional susceptibility variants remain to be identified.
Asians differ significantly from European descendants in genetic architectures. Genetic 
studies in Asians may provide an opportunity to explore the genetic architecture of 
colorectal cancer including identification of novel variants. We established the Asia 
Colorectal Cancer Consortium (ACCC) in 2010 to identify new genetic risk factors for 
colorectal cancer. Over the past 10 years, we have identified about 30 novel colorectal 
cancer risk loci (6–8, 11, 14). To further increase the statistical power of uncovering novel 
susceptibility loci for colorectal cancer, we utilized data from studies of 58,131 cases and 
67,347 controls of European ancestry (10) to replicate promising risk variants identified in 
GWAS of 23,572 cases and 48,700 controls recruited from 15 studies conducted in three 
East Asian Countries (China, Japan, and Korea). Furthermore, we performed conditional 
analyses to identify potential independent signals at each of the colorectal cancer risk loci 
identified in previous studies in Asians.
Materials and Methods
Overview of study population and study design
We recently reported results from a large GWAS conducted in the Asia Colorectal Cancer 
Consortium (ACCC) that identified 13 novel genetic loci for colorectal cancer risk (11). In 
this study, we increased the sample size further by including one additional study—the 
Korean-National Cancer Center CRC Study 2 (Korea-NCC2: 622 cases and 832 controls). 
Included in the current analysis were 23,572 colorectal cancer cases and 48,700 controls 
from 15 studies conducted in China, Japan, and South Korea (Supplementary Table S1; 
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Supplementary Data). To increase the statistical power, we used data from European 
descendants to replicate promising findings from the ACCC.
On the basis of the results from the meta-analysis of all Asian studies, we selected 60 
promising variants (P < 5 × 10−3, Supplementary Table S2) that are 500 kb away from any 
established colorectal cancer risk loci (10, 11) at the time of study design for replication 
using data from 58,131 cases and 67,347 controls of European descent (10). These cases and 
controls were derived from three colorectal cancer study consortia: the Genetics and 
Epidemiology of Colorectal Cancer Consortium (GECCO), the Colorectal Transdisciplinary 
(CORECT) Study, and the Colon Cancer Family Registry (CCFR). The details of each 
included study have been reported previously (9, 10). For this analysis, the Haplotype 
Reference Consortium panel without indel variants was used as reference for imputation.
All study protocols were approved by the relevant Institutional Review Boards (10, 11) and 
informed consents were obtained from study participants. Research was conducted in 
accordance with the Belmont report.
Genotyping and imputation
Details of genotyping, genotype calling, quality control and imputation for the ACCC have 
been reported previously (Supplementary Data; refs. 6–8, 11, 14). The genotypes for 
samples from six studies (Shanghai-4, Aichi-2, Korea-NCC, Korea-NCC2, Korea-Seoul, and 
HCES2-CRC; Supplementary Table S1) genotyped with Illumina MEGA-Expanded Array 
(Illumina Inc.) were updated on the basis of the manually reclustered genotype cluster files 
(for 123K SNPs). Little evidence of population stratification was found in these studies (6, 8, 
11), based on principal component (PC) analysis, using EIGENSTRAT (Supplementary Fig. 
S1; ref. 15). To increase the genome coverage and facilitate the meta-analysis, the 1000 
Genomes Project phase III mixed reference haplotypes (version 5) were used to impute 
untyped genotype data with Michigan Imputation Server (minimac3 for imputation and 
SHAPEIT for prephasing).
We evaluated the quality of imputation using whole-genome sequencing data for the five 
variants (rs67052019, rs60911071, rs62558833, rs11108175, and rs9634162; Supplementary 
Table S3) that were highly significantly associated with colorectal cancer risk. Data for these 
five variants were extracted from whole-genome sequence datasets for 290 Shanghai 
colorectal cancer samples and compared with the genotypes derived from the imputation-
based approach. The whole genome sequence was performed using the BGISEQ-500 
sequencing platform with paired-end reads in length with 2 × 100 bp (mean read depth 
~50M). The sequencing reads for each sample were mapped to the human reference genome 
(hg38) using the Burrows-Wheeler Aligner BWA program (version 0.75). The aligned reads 
were processed using the Genome Analysis ToolKit (GATKv3.7). Variant calling was 
performed individually for each sample with the GATK HaplotypeCaller tool and all 
samples together with GenotypeGVCFs to create a complete list of SNPs and indel VCFs. 
The Variant Quality Score Recalibration (VQSR) was then applied to filter variants of low 
quality.
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We used the score test implemented in Rvtest (16) to associate genotype dosages with 
colorectal cancer risk after adjusting for age, sex, and the first five PCs of each individual 
study. SNPs with a low imputation quality (R2 < 0.3) or a low MAF (<0.1% in the combined 
samples) were excluded from the downstream analysis. Summary statistics from each of 15 
ACCC case–control studies were meta-analyzed using METAL (17) with the inverse 
variance-weighted fixed effect model. Associations with a P < 5 × 10−8 in the Asian studies 
alone or in combination with European studies were regarded as genome-wide significant. 
Each independent locus was defined as ±500 kb on either side of the most significant SNP 
that reached a genome-wide significant threshold (P < 5 × 10−8). The Cochran Q test (18) 
was used to evaluate the heterogeneity across studies and subgroups. We did not observe any 
apparent inflation in association statistics from the ACCC (Supplementary Fig. S2; refs. 6, 8, 
11).
We performed approximate conditional analyses based on meta-analysis summary statistics 
to identify additional independent association signals at each locus using the GCTA-COJO 
method (19). The linkage disequilibrium (LD) matrix used in the analyses were based on 
6,684 unrelated East Asian samples (interindividual genetic relationships < 0.025; ref. 11). 
Considering relatively small sample sizes of colorectal cancer studies in populations of East 
Asian ancestry (10, 11), variants that are conditionally independent of the index SNPs within 
a region and reached an empirical locus-wide significance of P < 5 × 10−5 were considered 
to be distinct association signals.
In silico functional characterization of novel Ioci
To identify potential functional variants and target genes at novel risk loci identified in this 
study, we annotated all variants that are in LD (r2 ≥ 0.8, EAS in the 1000 Genomes Project; 
131 variants in total; Supplementary Table S4) with each of identified GWAS index variants 
within 500 kb using ANNOVAR (20). We used PolyPhen2 (21) and SIFT (22) to assess 
potential functional impact of coding variants. We further used regulatory information from 
the Roadmap Epigenomic project (epigenomic profiling) and the ENCODE project 
(regulatory protein binding and regulatory motifs) to characterize these 131 selected variants 
with the web-based HaploReg v4 (https://pubs.broadinstitute.org/mammals/haploreg/
haploreg.php) as described previously (11). We tested for enrichment of colorectal cancer 
index variants with functional domains using the software of Genomic Regulatory Elements 
and Gwas Overlap algoRithm (GREGOR;ref. 23). This method tests for an increase in the 
number of colorectal cancer-associated index variants (94 independent GWAS index variants 
identified in populations of East Asian ancestry at P < 5 × 10−8 or replicated in populations 
of East Asian ancestry at P < 5 × 10−2 for those variants originally identified in populations 
of European ancestry; Supplementary Table S5), or their LD proxies (r2 0.7, EAS in the 
1000 Genomes Project), overlapping with the regulatory features (peaks from H3K4me1 and 
H3K27ac as enhancers, peaks from H3K4me3 and H3K9ac as promoters, and open 
chromatin as measured by DNase hypersensitivity) more often than expected by chance by 
comparing to permuted control sets in which the variants are matched on variant frequency, 
number of LD proxies, and distance to the nearest gene. A saddle-point approximation was 
used to estimate the P value based on the distribution of permuted statistics (23).
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cis-expression quantitative trait loci analysis
We conducted cis-expression quantitative trait loci (cis-eQTLs) analyses for each of 
identified novel risk variants. The RNA was extracted from tumor-adjacent normal tissues 
obtained from 133 East Asian patients with colorectal cancer (7, 8, 11). We profiled gene 
expression using RNA sequencing with total mapped reads > 14M for each sample (11). We 
quantified gene expression levels using FPKM (Fragments Per Kilobase of transcript per 
Million mapped reads) values. For cis-eQTLs analyses, we defined as a region ±1 mb within 
each risk variant. These patients were genotyped using the Illumina MEGA array as 
described before (11). We used linear regression models to associate gene expression levels 
with SNP genotypes with adjustment for sex and the top two PCs. We also evaluated 
associations of novel risk variants with gene expressions in 246 transverse colon tissues 
included in the Genotype-Tissue Expression (GTEx) database (24).
Results
In the meta-analysis of all Asian data (23,572 colorectal cancer cases and 48,700 controls; 
Supplementary Table S1), we identified an indel variant at 1p13.3 (rs67052019) with an OR 
of 1.13 (95% CI = 1.08–1.18) for colorectal cancer risk per deletion copy at the genome-
wide significance level (P < 5 × 10−8; Table 1; Fig. 1; Supplementary Figs. S3 and S4). A 
variant (rs2938616) in complete LD with rs67052019 (D'EAS or EUR = 1.00, r2EAS or EUR = 
1.00) was associated with colorectal cancer risk in populations of European descent with OR 
of the deletion linked G allele = 1.03 (95% CI = 1.01− 1.04) and P = 7.7 10−3 (Table 1), and 
this variant was also associated with colorectal cancer risk in populations of Asian descent 
[OR of the deletion linked G allele = 1.10 (95% CI = 1.05–1.15) and P = 1.1 × 10−5; Table 
1].
Of the remaining 59 variants for replication in populations of European descent (58,131 
colorectal cancer cases and 67,347 controls; Supplementary Table S2), 12 variants were 
replicated in the same direction as observed in East Asian populations at P < 0.05. Three 
variants (rs4308634, rs11108175, and rs9634162) were identified to be associated with 
colorectal cancer risk at the genome-wide significance level (P < 5 × 10−8) in the combined 
meta-analysis results of East-Asians and Europeans (Table 1; Fig. 1; Supplementary Figs. S3 
and S4). However, the variant of rs4308634 [OR for the G allele = 1.04 (95% CI = 1.03–1.06) 
and P = 6.5 × 10−9 in the combined meta-analyses] at the 7p12.3 was in high LD (r2EAS = 
0.68) with a nearby variants (rs10951878) recently identified in populations of European 
ancestry (13). In addition, two variants (rs60911071 and rs62558833) were associated with 
colorectal cancer risk near the genome-wide significance level (P = 5.8 × 10−8 and 7.5 × 
10−8, respectively; Table 1; Fig. 1; Supplementary Fig. S4). Little heterogeneity of the effect 
size was observed between these two populations for these variants (P ≥ 0.01, Table 1). 
Stratification analyses of these newly identified risk variants (rs67052019, rs60911071, 
rs62558833, rs11108175, and rs9634162) by tumor site (colon or rectum) did not identify 
any significant heterogeneity (P > 0.05; Supplementary Table S6).
The average imputation quality for these five highly significant variants (rs67052019, 
rs60911071, rs62558833, rs11108175, and rs9634162) for colorectal cancer risk ranged 
from 0.78 to 0.99 in Asian cohorts and from 0.98 to 0.99 in European cohorts 
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(Supplementary Table S3). The overall genotype concordance rates for these five common 
variants (minor allele frequency ≥0.18; Table 1) between imputed data and whole-genome 
sequencing data were high (>0.90) based on 290 Shanghai colorectal cancer samples, 
indicating that the imputation quality was excellent for these SNPs (Supplementary Table 
S3).
Evaluation of local secondary signals
Independent secondary signals were reported in our previous studies for four colorectal 
cancer risk loci in East-Asian populations (EIF3H at 8q23.3, NKX2–3 at 10q24.2, VTI1A/
TCF7L2 at 10q25.2 and SMAD7 at 18q21.1; refs. 7, 8, 11, 14, 25). In this study, we 
observed 13 independent secondary signals at 11 additional loci in East Asians at the locus-
wide significance level (P < 5.0 × 10−5; SLCO2A1 at 3q22.2, PITX1 at 5q31.1, NOTCH4/
HLA-DRB1/HLA-DRB5 at 6p21.32, GATA3 at 10p14, PRICKLE1 at 12q12, LRP1/ 
ARHGAP9 at 12q13.3, MYL2/SH2B3 at 12q24.11, WWOX/MAF at 16q23.2, NXN at 
17p13.3, MYHAS/TMEM238L at 17p12 and BMP2 at 20p12.3; Table 2).
Functional characterization of risk loci and cis-eQTL analyses
We used functional genomics data to annotate each of the identified five novel variants 
(Table 1) as well as their correlated variants (r2EAS ≥ 0.80).Aligning these risk variants with 
histone methylation/acetylation marks and DNase hypersensitivity sites (26) revealed that 
variants at three loci (1p13.3, 8p21.2, and 12q22) overlapped with the promoter/enhancer 
histone marks or DNase hypersensitivity sites in gastrointestinal tissues (Supplementary 
Table S4). This suggests that these variants may be involved in regulating gene expressions 
in gastrointestinal tissues. We further tested for tissue regulatory element enrichments of 94 
colorectal cancer–associated variants identified or replicated in populations of East Asian 
ancestry (Supplementary Table S5 and Materials and Methods) using GREGOR (23). We 
found that colorectal cancer-associated variants were strongly associated with regulatory 
elements in gastrointestinal tissues (fetal stomach, fetal small intestine, fetal large intestine, 
small intestine, sigmoid colon, colonic mucosa, rectal mucosa, and stomach mucosa; >2.0 × 
enrichment; Supplementary Tables S7 and S8). Interestingly, monocytes were also enriched 
as indicated by DNase I hypersensitive sites (P = 8.1 10−13, 2.3 × enrichment; 
Supplementary Tables S7 and S8). Similar results were observed on the basis of colorectal 
cancer-associated variants identified separately in populations of East Asian ancestry (fetal 
stomach, fetal small intestine, fetal large intestine, sigmoid colon, rectal mucosa, stomach 
mucosa, and monocytes; >2.0 × enrichment and P < 7.2 × 10−6) or populations of European 
ancestry (fetal stomach, fetal small intestine, fetal large intestine, sigmoid colon, colonic 
mucosa, and rectal mucosa; >2.0 × enrichment and P < 6.7 × 10−10).
We performed cis-eQTL analyses using transcriptome data from tumor-adjacent normal 
colon tissues from 133 patients with colorectal cancer of East Asian ancestry 
(Supplementary Table S9) and transverse colon tissues from 246 individuals predominantly 
of European ancestry in the GTEx (Supplementary Table S10). Significant correlations at P 
< 0.05 were found for 3 and 6 SNP–gene expression pairs in the East Asian and GTEx 
datasets, respectively. The colorectal cancer risk (deletion) allele of rs67052019 was 
associated with reduced expression of UBL4B and GPR61, but increased expression of 
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KCNC4-AS1 (consistent between the East Asian and GTEx datasets) and TMEM167B. The 
colorectal cancer risk T allele of rs62558833 was associated with increased expression of 
SMU1, DCAF12, and NUDT2. The CRC risk A allele of rs11108175 was associated with 
increased expression of VEZT.
Discussion
In this meta-analysis of 23,572 colorectal cancer cases and 48, 700 controls in East-Asians 
and follow-up replication analyses of 58,131 colorectal cancer cases and 67, 347 controls in 
individuals of European descent, we identified three novel risk loci and two highly 
suggestive loci for colorectal cancer risk. In addition, we identified 13 secondary signals at 
11 known colorectal cancer risk loci in East Asians. Using functional genomics data, we 
showed that three of the newly identified risk variants, or their highly correlated variants, are 
located in regulatory regions of the genome. It indicates that these variants potentially 
regulate the expression of nearby genes in gastrointestinal tissues. In addition, monocytes 
were implicated in colorectal cancer carcinogenesis for the first time based on tissue 
regulatory element enrichment analyses. Our cis-eQTL analyses provide additional supports 
for a possible role of several risk variants identified inour study in regulating expression of 
cancer-related genes. Our study provides novel information toward the understanding of the 
genetic and biological basis of colorectal cancer.
At the 1p13.3 locus, the deletion allele of rs67052019 was associated with increased 
colorectal cancer risk. The variant rs67052019 was 58.8 Kb upstream of the EPS8L3 gene. 
The function of the encoded protein by EPS8L3 is unknown. Interestingly, the deletion allele 
of rs67052019 was associated with increased KCNC4-AS1 (KCNC4 antisense RNA) 
expression in both Asian and GTEx datasets. The encode protein by KCNC4 is the voltage 
gated Kv3.4 potassium channel protein involved in regulating mammalian cellcycle (27, 28). 
Theroles of Kv channels in cancer development and progression have been well established, 
and they are not only involved in cell proliferation and tumor growth, but also in cell 
migration and metastasis (29, 30).
At the 8p21.2 locus, rs60911071 is 35 kb downstream of STC1. Another variant (rs2928679, 
r2EAS or EUR = 0.0, between rs60911071 and rs2928679) in this region was reported to be 
associated with prostate cancer risk in populations of European ancestry (31). The encoded 
protein by STC1 is a secreted glycoprotein, and is expressed ubiquitously, including in the 
gastrointestinal tract. STC-1 is reported to mediate the metastatic effect of platelet-derived 
growth factor signaling in colorectal cancer–associated fibroblasts (32). High expressions of 
STC1 are correlated with poor postoperative survival in patients with colorectal cancer (33).
At the 9p13.3 locus, rs62558833 is an intronic variant of UBAP2. The encoded protein by 
UBAP2 functions in the ubiquitination pathway. It inhibits the invasion of hepatocellular 
carcinoma cell by ubiquitinating and degrading Annexin A2 (34). The colorectal cancer risk 
T allele of rs62558833 was associated with an increased expression of SMU1 
(Supplementary Table S9), DCAF12, and NUDT2 (Supplementary Table S10). The encoded 
protein by SMU1 is suggested to be involved in genome stability maintenance by negatively 
regulating DNA synthesis (35). The encoded protein by DCAF12 is required for 
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developmental apoptosis (36). The encoded protein by NUDT2 is suggested to be a tumor-
promoting factor, and high expressions of NUDT2 are associated with poor prognosis and an 
increased risk of breast cancer recurrence (37, 38).
At the 12q22 locus, rs11108175 is a downstream variant of NTN4. Another nearby variant 
of rs17356907 (r2EAS or EUR = 0.0,between rs11108175 and rs17356907) was reported to be 
associated with breast cancer risk in European populations (39). NTN4 encodes a member of 
the netrin family of proteins that functions in various biological processes, including axonal 
guidance, tumorigenesis, and angiogenesis (40). NTN4 overexpression is observed to 
suppress primary and metastatic colorectal tumor progression through inhibiting tumor 
growth and angiogenesis (41–43). The colorectal cancer risk A allele of rs11108175 was 
nominally associated with an increased VEZT expression (Supplementary Table S10). The 
encode protein by VEZT is a ubiquitous transmembrane protein that is localized to adherens 
junctions in epithelial cells (44). How the aberrant expression of VEZT affects colorectal 
cancer risk warrants further investigations.
At the 12q24.21 locus, rs9634162 is 9.9 kb downstream of the TBX3 gene. Two nearby 
variants, rs59336 (P = 3.7 × 10−7 on colorectal cancer risk, r2EAS = 0.58 and r2EUR = 0.66 
between rs9634162 and rs59336) (45) and rs1427760 (P = 2.5 × 10−7 on colorectal cancer 
risk, r2EAS = 0.78 and r2EUR = 0.89 between rs9634162 and rs1427760; ref. 10) were 
reported to be associated with colorectal cancer risk in populations of European ancestry. We 
established this locus as one of the bona fide colorectal cancer risk loci at genome-wide 
significance. The protein encoded by TBX3 belongs to the evolutionarily conserved T-box 
family of transcription factors that play critical roles in early embryonic development. 
Overexpression of Tbx3 is associated with multiple cancers potentially by modulating cell 
proliferation and survival, tumor formation and metastasis, and drug resistance (46). 
Emerging evidence suggests that Tbx3 is not only important for stem cell self-renewal, but 
also is extensively involved in cancer stemness (46, 47).
Independent secondary signals were observed at colorectal cancer risk loci in both East-
Asian populations (7, 8, 11, 14, 25) and European populations (10, 13, 48–51). We observed 
13 independent secondary signals at 11 additional colorectal cancer loci in East Asians. 
Conditional joint analysis could refine association signals and uncover additional GWAS 
loci for colorectal cancer. The loci of MYL2/SH2B3 at 12q24.11 and LRP1/ARHGAP9 at 
12q13.3 that were reported in European populations for colorectal cancer risk (10, 52) only 
reached the genome-wide significance in the conditional joint analysis in East Asians. The 
missense variants of rs78894077 in SH2B3 at 12q24.11 only exist in East Asian populations 
(Table 2) and is predicted to be highly “deleterious” in both PolyPhen2 (21) and SIFT (22). 
This strongly implicates that SH2B3 is the underlying causal gene for colorectal cancer risk 
at this locus. The low-frequency intronic variant of rs368674461 in MYHAS at 17p12 also 
only exists in East Asian populations (Table 2); however, the function of MYHAS is 
currently unknown.
In summary, we identified three novel variants and two highly suggestive loci for colorectal 
cancer risk in this large GWAS of colorectal cancer. Combining information from functional 
annotations, cis-eQTL analyses and literature review, we propose the putative candidate 
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genes for these loci: KCNC4-AS1 at 1p13.3, STC1 at 8p21.2, NUDT2 at 9p13.3, NTN4 at 
12q22, and TBX3 at 12q24.21. Some of the putative target genes suggested by the results 
from our studies are located in established pathways for colorectal tumorigenesis, such as 
the maintaining of colon stem cells (TBX3). Multiple independent signals exist at many 
colorectal cancer loci; therefore, more familial relative risk of colorectal cancer could be 
explained at a locus when multiple independent signals were considered. However, extensive 
fine-mapping and functional follow-up studies are needed to identify the causal variants and 
target genes at each of the identified regions.
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Regional association plots of five colorectal cancer risk loci in Asian descendants (A, 
rs67052019; B, rs60911071; C, rs62558833; D, rs11108175; and E, rs9634162). Each dot 
represents the P value (on a log10 scale) of an SNP with colorectal cancer risk based on the 
meta-analysis results in East Asians only and is presented according to its genomic position 
(NCBI Build 37). The most significantly associated SNP in the combined meta-analyses is 
represented by purple. The color of all other SNPs indicates the level of LD with the lead 
SNP (estimated by ASN r2 from the 1000 Genome Project data). Recombination rates were 
also estimated from 1000 Genomes Project data, and gene annotations within the 2 Mb 
regions that are centered on the newly identified risk variants were obtained from the UCSC 
Genome Browser.
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Table 1.






East Asian descendants (up 
to 23,572 cases and 48,700 
controls)
European descendants (up 







P Phet RAF OR 
(95% 
CI)




Loci reaching genome-wide significance with P < 5 × 10−8











b – – – – –




































Loci near genome-wide significance with P <1 × 10−7 but > 5 × 10−8




































Abbreviations: alleles, risk allele/reference allele; CI, confidence interval; Phet: P value derived from the heterogeneity test; RAF, risk allele 
frequency.
a
Del: deletion for ACAGAGAGATGTAGGGGC.
b
Variant of rs2938616 (D’EAS or EUR = 1.00, r2EAS or EUR = 1.00 with rs67052019) was associated with colorectal cancer risk in populations 
of European ancestry [OR for the deletion linked G allele of rs2938616 = 1.03 (95% CI = 1.01–1.04) and P = 7.7 × 10−3] and in populations of 
East Asian ancestry [OR of the deletion linked G allele of rs2938616 = 1.10 (95% CI = 1.05–1.15) and P = 1.1 × 10−5].
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